Assenagon Asset Management
ATRA icon

Assenagon Asset Management’s Atara Biotherapeutics ATRA Stock Holding History

Assenagon Asset Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-24,040
Closed -$1.97M – 1405
2022
Q4 		$1.97M Hold
24,040
– – 0.01% 818
2022
Q3 		$2.27M Sell
24,040
-211
-0.9% -$23.7K 0.01% 667
2022
Q2 		$4.72M Sell
24,251
-4,936
-17% -$806K 0.02% 562
2022
Q1 		$6.78M Sell
29,187
-48,766
-63% -$15.5M 0.02% 464
2021
Q4 		$30.7M Buy
77,953
+17,564
+29% +$7.39M 0.09% 159
2021
Q3 		$27M Buy
60,389
+512
+0.9% +$183K 0.09% 178
2021
Q2 		$23.3M Buy
+59,877
New +$21.4M 0.08% 206
2020
Q3 		– Sell
-30,948
Closed -$11.3M – 1117
2020
Q2 		$11.3M Buy
+30,948
New +$7.82M 0.07% 171
2020
Q1 		– Sell
-16,849
Closed -$6.94M – 790
2019
Q4 		$6.94M Buy
+16,849
New +$5.81M 0.04% 209
2018
Q4 		– Sell
-16,621
Closed -$17.2M – 995
2018
Q3 		$17.2M Buy
16,621
+7,114
+75% +$6.96M 0.17% 121
2018
Q2 		$8.73M Buy
9,507
+4,018
+73% +$4.32M 0.1% 190
2018
Q1 		$5.35M Buy
+5,489
New +$5M 0.07% 221

Other funds holding ATRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Assenagon Asset Management's ATRA Position: Q1 2023 in Review

Assenagon Asset Management sold out of Atara Biotherapeutics (ATRA) in Q1 2023, closing a stake of 24,040 shares — an estimated $1.97M sold.

Assenagon Asset Management first reported a position in ATRA in Q1 2018 and held it in 12 quarters. The position peaked at $30.7M in Q4 2021. 125 funds tracked by Wall St. Rank hold ATRA as of Q1 2023.

  • Assenagon Asset Management reported no remaining Atara Biotherapeutics position as of Q1 2023 after selling out during the quarter.
  • Assenagon Asset Management sold 24,040 Atara Biotherapeutics shares in Q1 2023, an estimated $1.97M.
  • Assenagon Asset Management first reported a position in Atara Biotherapeutics in Q1 2018 and held it in 12 quarters.
  • Assenagon Asset Management's Atara Biotherapeutics position peaked at $30.7M in Q4 2021.
  • 125 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2023.

Based on Assenagon Asset Management's 13F filing for Q1 2023, filed 18 Apr 2023.